查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018707

果凍市場：2026-2032年全球市場預測（按產品類型、材料類型、生物吸收性、應用和最終用戶分類）

Biosurgery Market by Product Type, Material Type, Resorbability, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，果凍市場價值將達到 185.8 億美元，到 2026 年將成長至 201.4 億美元，到 2032 年將達到 334.3 億美元，複合年成長率為 8.75%。

主要市場統計數據
基準年 2025 185.8億美元
預計年份：2026年 201.4億美元
預測年份 2032 334.3億美元
複合年成長率 (%) 8.75%

果凍正迅速成為現代醫學中至關重要的領域，它將生物活性材料應用於各種外科手術，以支持組織修復、止血和組織粘連。微創手術需求的日益成長，以及生物材料科學的進步，正推動該領域走向創新前沿。相關人員身處在一個動態變化的環境中，面臨著不斷變化的法規結構、日益嚴格的成本限制，以及在日益複雜的患者群體中驗證臨床療效的必要性。

果凍領域的創新步伐正因材料科學家、工程師和臨床專業人員之間的跨學科合作而加快，他們致力於最佳化產品的性能和安全性。將新型膠原蛋白、纖維蛋白和合成基質轉化為可規模化生產的產品，需要嚴格的檢驗和與現有手術流程的精心整合。同時，監管機構正在完善核准流程，以平衡病人安全和及時取得產品，並敦促製造商積極參與對話和證據收集。

本執行摘要全面概述了影響果凍市場的變革性因素，包括技術突破、政策趨勢以及醫療服務提供者優先事項的轉變。它闡明了近期價格調整的影響，分析了產品類型、材料、吸收特性、臨床應用和終端用戶場景等關鍵細分方面，並重點介紹了細微的區域趨勢。讀者將獲得關於競爭定位、夥伴關係機會以及未來關鍵決策點的策略性清晰認知。

揭示推動果凍創新並重塑全球醫療保健產業競爭格局的模式轉移。

近年來，隨著具有優異生物相容性和精準作用機制的先進止血劑、黏合劑和組織移植技術的出現，果凍經歷了範式轉移。纖維蛋白密封劑和合成聚合物的創新為有效止血和組織再生開闢了新途徑。此外，跨學科舉措正在推動下一代複合材料的研發，這些材料整合了抗菌和生長因子功能，旨在簡化術後復健過程。

評估美國 2025 年關稅調整對生物外科供應鏈、成本結構和策略採購慣例。

美國當局於2025年實施的修訂版關稅表，對從國際供應商採購的生物外科材料和醫療設備新增了一項成本因素。這些調整導致進口價格受到更嚴格的審查，迫使製造商重新評估供應商選擇和供應鏈結構。因此，採購團隊正在探索多種採購模式，包括近岸外包和區域夥伴關係，以穩定投入成本並降低全球貿易中斷帶來的波動風險。

發布核心細分框架，明確生物外科產品在產品種類、材料、吸收性、應用和最終用戶畫像方面的多樣化路徑。

產品類型分析揭示了止血劑、密封劑和黏合劑以及組織移植物的清晰發展軌跡。止血劑不斷發展，透過改進吸收動力學和可客製化的劑型，應對高風險手術中的出血挑戰。密封劑和黏合劑受益於將強黏合力與生物相容性載體系統結合的配方。包括無細胞基質和細胞構建體在內的組織移植物正在不斷改進，以改善組織整合和功能恢復，並應用於各個外科領域。

闡明影響美洲、歐洲、中東、非洲和亞太地區果凍發展軌跡的區域趨勢。

在美洲，對醫療基礎設施的大力投資以及對微創手術的高度重視正在推動市場成長。在北美，監管支持和報銷機制促進了高品質生物外科產品的普及；而在拉丁美洲，市場正透過有針對性的官民合作關係和能力建設舉措而蓬勃發展。這種區域差異為製造商提供了契機，使其能夠根據資源環境和患者就醫需求的差異，調整產品系列。

領先果凍公司的策略性舉措和創新路線：憑藉尖端解決方案和合作夥伴關係躍居競爭前沿

果凍領域的主要企業正採取差異化策略以保持競爭優勢。一些企業優先收購利基技術公司，以增強產品平臺，並獲得新型生物材料和先進遞送系統的專業知識。另一些企業則加大內部研發投入，建立專門的研發中心，研究下一代複合材料和生物活性支架。與學術機構和合約研究組織 (CRO) 的合作也有助於開展探索性研究，為未來的產品上市提供支援。

為產業領導者提供切實可行的建議，以因應果凍領域的變革，利用技術進步，並確立市場領導地位。

對於希望在瞬息萬變的貿易環境中游刃有餘的企業而言，投資建構高度靈活的供應鏈策略至關重要。建立多元化的採購管道，包括區域性製造地和經認證的合約合作夥伴，能夠有效降低價格不確定性和物流瓶頸。積極與海關當局和認證機構合作，也能簡化進口流程，避免代價高昂的延誤。透過增強採購系統的韌性，企業可以確保業務永續營運，並保護利潤率免受未來地緣政治格局變化的影響。

透過結合一手研究、二手分析和定量建模的嚴謹多方法調查方法，揭示了果凍市場的真實情況。

本研究採用多維度的研究框架，結合關鍵相關人員的訪談、二手文獻分析和定量建模，以全面了解生物外科領域的現狀。與外科醫生、採購負責人、監管專家和產品經理的深入對話，為我們提供了關於未滿足的需求、創新促進因素和推廣障礙的第一手觀點。同時，已發表的臨床試驗、專利申請和政策白皮書的系統性回顧，強化了研究的背景基礎，並促進了定性輸入與文獻證據之間的交叉檢驗。

本報告整合了關鍵見解和策略結論，旨在為不斷發展的全球果凍生態系統中的相關人員提供指導。

本概要分析著重闡述了生物外科領域的現狀，該領域正處於快速技術創新和不斷變化的經濟因素的交匯點。先進材料和針對特定應用的遞送系統正在重新定義醫療標準，而關稅調整和監管變化既帶來了機遇，也帶來了挑戰。積極適應這些趨勢，並透過多元化供應鏈、策略夥伴關係和敏捷開發流程來應對挑戰的相關人員，將更有能力塑造外科手術的未來發展方向。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：果凍市場：依產品類型分類

  • 止血裝置
  • 密封劑和黏合劑
  • 組織移植

第9章：果凍市場：依材料類型分類

  • 膠原蛋白蛋白
  • 纖維蛋白系統
  • 明膠基
  • 合成

第10章：果凍市場－生物吸收

  • 不吸收
  • 吸收性
    • 完全吸收
    • 部分吸收

第11章：果凍市場：依應用領域分類

  • 心血管外科
    • 心臟繞道手術
    • 閥門維修
  • 一般外科
    • 疝氣修補術
    • 傷口修復
  • 微創手術
    • 內視鏡
    • 腹腔鏡
  • 開放性手術
  • 整形外科手術
    • 關節重建手術
    • 脊椎融合手術

第12章：果凍市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所
    • 牙醫診所
    • 眼科診所

第13章：果凍市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：果凍市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章果凍市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國果凍市場

第17章：中國果凍市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Advanced Medical Solutions Group plc
  • Artivion, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BioCer Entwicklungs-GmbH
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Corza Medical GmbH
  • CryoLife, Inc.
  • CSL Limited
  • Hemostasis, LLC
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson
  • Kuros Bioscience AG
  • Medtronic plc
  • Pfizer Inc.
  • RTI Surgical, Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Smith & Nephew plc
  • Stryker Corporation
  • Teleflex Incorporated
  • Tissue Regenix Ltd
  • Vivostat A/S
Product Code: MRR-AD36CD8982F7

The Biosurgery Market was valued at USD 18.58 billion in 2025 and is projected to grow to USD 20.14 billion in 2026, with a CAGR of 8.75%, reaching USD 33.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 18.58 billion
Estimated Year [2026] USD 20.14 billion
Forecast Year [2032] USD 33.43 billion
CAGR (%) 8.75%

Biosurgery has emerged as a pivotal domain within modern healthcare, integrating biologically active materials to support tissue repair, hemostasis, and adhesion in a range of surgical interventions. The growing demand for minimally invasive procedures, coupled with advances in biomaterials science, has propelled this field to the forefront of innovation. Stakeholders are navigating a dynamic environment characterized by evolving regulatory frameworks, heightened cost constraints, and the necessity to demonstrate clinical efficacy across increasingly complex patient populations.

The pace of innovation in biosurgery is being accelerated by cross-disciplinary collaboration among material scientists, engineers, and clinical specialists seeking to optimize performance and safety profiles. Translation of novel collagen, fibrin, and synthetic matrices into scalable products requires rigorous validation and thoughtful integration with existing surgical workflows. Concurrently, regulatory bodies are refining pathways to balance patient safety with timely access, encouraging manufacturers to engage in proactive dialogue and evidence generation.

This executive summary presents a cohesive exploration of the transformative forces shaping the biosurgery market, encompassing technological breakthroughs, policy developments, and shifting provider priorities. It articulates the implications of recent tariff adjustments, dissects core segmentation dimensions across product types, materials, resorbability characteristics, clinical applications, and end user contexts, and surfaces nuanced regional dynamics. Readers will gain strategic clarity on competitive positioning, partnership opportunities, and critical decision points ahead.

Mapping the Paradigm Shifts Driving Biosurgery Innovations and Reconfiguring Competitive Landscapes across Global Healthcare Sectors

In recent years, biosurgery has undergone paradigm-defining transformations driven by the emergence of advanced hemostatic agents, bioadhesives, and tissue graft technologies that offer superior biocompatibility and mechanistic precision. Innovations in fibrin-based sealants and synthetic polymers have unlocked new avenues for effective bleeding control and tissue regeneration. Moreover, multidisciplinary research initiatives are fueling the development of next-generation composites that integrate antimicrobial and growth factor functionalities to streamline postoperative recovery.

Simultaneously, the proliferation of minimally invasive and robotic-assisted techniques has elevated expectations for device design, demanding materials that adhere reliably within constrained working spaces. Surgeons are increasingly seeking solutions that combine ease of deployment with robust performance under physiological stress. This shift is catalyzing partnerships between instrument developers and biomaterial manufacturers aiming to deliver integrated systems that enhance precision, reduce operative times, and minimize patient trauma.

Looking ahead, the convergence of digital health platforms with biosurgery promises to redefine procedural planning, intraoperative guidance, and postoperative monitoring. Data-driven insights derived from real-world evidence studies are informing iterative product refinements, while artificial intelligence algorithms are being explored to predict patient-specific outcomes. These collective advancements are set to elevate biosurgical interventions, fostering a more proactive and personalized approach to tissue repair and hemostasis.

Assessing the Ripple Effects of United States Tariff Adjustments on Biosurgery Supply Chains, Cost Structures, and Strategic Sourcing Practices in 2025

The implementation of revised tariff schedules by United States authorities in 2025 has introduced a new cost dimension for biosurgical materials and devices sourced from international suppliers. These adjustments have heightened scrutiny on import pricing and compelled manufacturers to reevaluate both vendor selection and supply chain architecture. As a result, procurement teams are exploring diversified sourcing models, including nearshoring and regional partnerships, to stabilize input costs and mitigate volatility associated with global trade disruptions.

Beyond direct cost implications, the tariff changes have influenced global competitive dynamics, as domestic producers of hemostats, sealants, and grafts experience a relative advantage in their home markets. International companies are contemplating strategic investments in local manufacturing facilities or contractual alliances to preserve market access and maintain optimal lead times. Such moves underscore a broader trend toward supply chain resilience informed by geopolitical sensitivities and regulatory compliance mandates.

In parallel, tariffs have prompted manufacturers to intensify value engineering efforts, seeking to optimize formulations and reduce reliance on high-cost raw materials without compromising efficacy. Collaborative research agreements and joint ventures are gaining traction as a means to share development costs and expedite the co-creation of innovative products. Ultimately, these strategic adaptations aim to safeguard profitability while ensuring that patients continue to benefit from state-of-the-art biosurgical technologies.

Unveiling Core Segmentation Frameworks Illuminating Diversification Paths in Biosurgery Product Offerings, Materials, Resorbability, Applications, and End User Profiles

Analysis of product categories reveals distinct trajectories for hemostats, sealants and adhesives, and tissue grafts. Hemostatic agents continue to evolve with enhanced absorption kinetics and customizable delivery formats that address bleeding challenges in high-risk procedures. Sealants and adhesives are benefiting from formulations that combine robust bonding strength with biocompatible carrier systems. Tissue graft offerings, including acellular matrices and cellularized constructs, are being refined to improve integration and functional recovery across surgical disciplines.

Material innovations are driving differentiation across collagen-based, fibrin-based, gelatin-based, and synthetic constructs. Collagen matrices are prized for their natural biocompatibility and structural support, while fibrin-derived sealants capitalize on endogenous clotting cascades to reinforce hemostasis. Gelatin-based platforms offer versatile gelation properties that can be tuned for targeted applications, and synthetic polymers provide consistent performance characteristics and reduced immunogenicity. Each material class is undergoing iterative enhancements aimed at optimizing mechanical resilience and degradation profiles.

Resorbability characteristics play a critical role in clinical decision making, with nonresorbable options favored when long-term scaffold stability is required, and resorbable alternatives increasingly adopted to minimize foreign body presence. Fully resorbable materials degrade completely over a predetermined timeframe, supporting temporary support before safe clearance, while partially resorbable systems combine enduring frameworks with degradable components to balance structural needs with eventual absorption. This nuanced spectrum enables tailored therapeutic strategies across patient populations.

Application-specific segmentation underscores the importance of matching device properties to procedural requirements. Cardiovascular surgeries, including bypass operations and valve repairs, demand high-tensile strength adhesives and leak-resistant matrices. General surgical contexts such as hernia repair and wound management leverage lightweight scaffolds and malleable sealants for tissue approximation. Minimally invasive approaches, whether endoscopic or laparoscopic, call for delivery mechanisms compatible with narrow lumens. Orthopedic interventions, spanning joint replacement and spinal fusion, require load-bearing grafts. End user settings vary from ambulatory surgery centers to tertiary hospitals and specialty clinics in dental and ophthalmology practices.

Deciphering Regional Trends Shaping Biosurgery Growth Trajectories across the Americas, Europe Middle East & Africa, and the Asia-Pacific Domain

In the Americas, market growth is being driven by robust investment in healthcare infrastructure and a strong emphasis on minimally invasive procedures. North American regulatory support and reimbursement frameworks are encouraging adoption of premium biosurgical products, while Latin American markets are emerging through targeted public-private partnerships and capacity-building initiatives. This regional diversity presents opportunities for manufacturers that can tailor their portfolios to address varying resource environments and patient access considerations.

Europe, Middle East, and Africa represent a heterogeneous landscape where established Western European markets coexist with evolving economies across the Middle East and North Africa. In Western Europe, cost-containment pressures and rigorous clinical guidelines are prompting value-based adoption of biosurgical solutions. Simultaneously, the Gulf Cooperation Council countries are investing heavily in advanced medical facilities, creating demand for cutting-edge hemostatic and regenerative devices. Market entrants that navigate complex regulatory matrices and foster local collaborations are well positioned to capitalize on this spectrum.

Asia-Pacific is characterized by dynamic growth fueled by expanding healthcare access, rising surgical volumes, and government initiatives to fortify domestic manufacturing capabilities. Established markets such as Japan and Australia demand high-quality, certified products, whereas emerging economies in Southeast Asia and the Indian subcontinent are seeking affordable yet effective biosurgical interventions. Strategic alliances and technology transfer agreements are enabling global players to penetrate these markets, while regional innovators are advancing homegrown solutions tailored to local clinical needs.

Highlighting Strategic Moves and Innovation Pipelines among Leading Biosurgery Companies Forging the Competitive Frontier with Cutting-Edge Solutions and Collaborations

Leading players in the biosurgery arena are pursuing differentiated strategies to maintain competitive advantage. Some have prioritized acquisitions of niche technology firms to bolster their product pipelines, acquiring expertise in novel biomaterials and advanced delivery systems. Others are channeling resources into in-house R&D, establishing dedicated innovation centers to explore next-generation composites and bioactive scaffolds. Collaborations with academic institutions and contract research organizations are also fueling exploratory studies that underpin future product launches.

In addition to internal development, strategic partnerships are reshaping the ecosystem, with some companies entering co-development agreements to streamline regulatory pathways and share commercial risks. Joint ventures with regionally specialized manufacturers are enabling optimized production footprints and faster market access. Meanwhile, smaller, agile firms are carving distinct market positions by concentrating on adjacent therapeutic niches and demonstrating clinical superiority through targeted investigator-initiated trials. These varied approaches are collectively enriching the innovation pipeline.

Competitive dynamics are further influenced by concerted efforts to expand into new geographic territories and clinical segments. Entities with strong distribution networks in upstream specialties are branching into complementary areas, leveraging existing relationships to cross-sell biosurgical offerings. Simultaneously, investment in digital marketing and educational initiatives is equipping healthcare professionals with the knowledge required to adopt advanced technologies. These strategic maneuvers underscore a broader trend toward integrated solutions that transcend traditional product silos.

Empowering Industry Leaders with Pragmatic Recommendations to Navigate Disruption, Leverage Technological Advancements, and Cement Market Leadership in Biosurgery

Investing in adaptive supply chain strategies will be imperative for companies seeking to navigate the evolving trade environment. Establishing multiple sourcing lanes, including regional manufacturing hubs and qualified contract partners, can alleviate price unpredictability and logistical bottlenecks. Proactive engagement with customs authorities and certification bodies will also streamline import processes and prevent costly delays. By building resilience into procurement frameworks, organizations can safeguard operational continuity and protect profit margins against future geopolitical fluctuations.

Prioritizing innovation through cross-functional collaboration can accelerate the translation of novel biomaterials into market-ready solutions. Creating interdisciplinary teams that bring together clinical advisors, engineering specialists, and regulatory affairs experts fosters holistic product development and reduces time to market. In parallel, adopting an agile methodology for iterative design and validation allows for rapid refinement based on user feedback and real-world performance data. This approach ensures that new offerings consistently meet evolving clinician and patient needs.

Expanding strategic footprint within key regions requires tailored commercialization blueprints that reflect local reimbursement dynamics and clinical practices. Companies should invest in market intelligence and stakeholder mapping to identify high-impact entry points and partnership prospects. Cultivating relationships with leading healthcare professionals and opinion leaders can accelerate trial adoption and generate credible evidence to support broader uptake. Through targeted educational initiatives and value demonstration programs, firms can establish sustainable competitive moats in diverse geographies.

Enhancing digital capabilities and data analytics is vital for unlocking deeper insights into procedural outcomes and customer preferences. Implementing robust feedback loops via digital platforms enables continuous product improvement and personalized engagement. Moreover, leveraging predictive analytics to identify emerging clinical trends and procurement patterns empowers commercial teams to proactively position their portfolios. By aligning digital transformation efforts with core business objectives, industry leaders can capitalize on untapped growth opportunities within the biosurgery domain.

Detailing a Rigorous Multimethod Research Methodology Integrating Primary Insights, Secondary Analysis, and Quantitative Modeling to Illuminate Biosurgery Market Realities

This study integrates a multimethod research framework combining primary stakeholder interviews, secondary literature analysis, and quantitative modeling to ensure comprehensive coverage of the biosurgery landscape. In-depth conversations with surgeons, procurement specialists, regulatory experts, and product managers provided first-hand perspectives on unmet needs, innovation drivers, and adoption barriers. Concurrently, a systematic review of published clinical trials, patent filings, and policy white papers enriched the contextual foundation and facilitated triangulation of qualitative inputs with documented evidence.

Quantitative modeling efforts employed robust statistical techniques and sensitivity analyses to explore relationships between key variables such as material properties, procedural volumes, and cost parameters. Data inputs were sourced from peer-reviewed journals, global health organization reports, and public regulatory databases. Regional market maps were constructed using a geospatial approach, enabling visualization of demand concentrations and growth corridors. This quantitative backbone was iteratively validated against primary insights to refine accuracy and coherence.

Quality assurance protocols were implemented throughout the research process, including peer review of analytical outputs, data integrity checks, and validation workshops with external subject matter specialists. Each phase of the methodology adhered to established best practices in market and clinical research, ensuring that conclusions are grounded in both empirical rigor and real-world relevance. This comprehensive approach underpins the credibility of the findings and recommendations presented in this executive summary.

Synthesizing Crucial Findings and Strategic Conclusions to Illuminate the Path Forward for Stakeholders in the Evolving Biosurgery Ecosystem Worldwide

Collectively, the analyses highlighted in this summary illustrate a biosurgery sector at the intersection of rapid technological innovation and shifting economic forces. Advanced materials and application-specific delivery systems are redefining standards of care, while tariff adjustments and regulatory evolutions introduce both opportunities and constraints. Stakeholders who proactively adapt to these dynamics-through supply chain diversification, strategic partnerships, and agile development processes-will be best positioned to shape the future trajectory of surgical interventions.

The segmentation and regional assessments underscore a market characterized by granularity and heterogeneity, where success depends on nuanced understanding of material performance, procedure requirements, and local healthcare landscapes. Leading companies are aligning R&D pipelines with emerging clinical needs and forging collaborative models to accelerate commercial access. As data-driven methodologies and digital tools assume greater prominence, the capacity to generate and act upon actionable intelligence will differentiate market leaders from late adopters.

In sum, this executive summary offers a strategic compass for decision-makers seeking to navigate the complexities of the biosurgery ecosystem. By synthesizing critical insights related to technology trends, policy shifts, segmentation nuances, and competitive behaviors, it equips stakeholders with the clarity needed to make informed investment, development, and commercialization choices. The path forward will demand both visionary leadership and operational excellence to realize the full potential of biosurgical innovations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biosurgery Market, by Product Type

  • 8.1. Hemostats
  • 8.2. Sealants & Adhesives
  • 8.3. Tissue Grafts

9. Biosurgery Market, by Material Type

  • 9.1. Collagen-Based
  • 9.2. Fibrin-Based
  • 9.3. Gelatin-Based
  • 9.4. Synthetic

10. Biosurgery Market, by Resorbability

  • 10.1. Nonresorbable
  • 10.2. Resorbable
    • 10.2.1. Fully Resorbable
    • 10.2.2. Partially Resorbable

11. Biosurgery Market, by Application

  • 11.1. Cardiovascular Surgery
    • 11.1.1. Bypass Surgery
    • 11.1.2. Valve Repair
  • 11.2. General Surgery
    • 11.2.1. Hernia Repair
    • 11.2.2. Wound Repair
  • 11.3. Minimally Invasive Surgery
    • 11.3.1. Endoscopic
    • 11.3.2. Laparoscopic
  • 11.4. Open Surgery
  • 11.5. Orthopedic Surgery
    • 11.5.1. Joint Replacement
    • 11.5.2. Spinal Fusion

12. Biosurgery Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics
    • 12.3.1. Dental Clinics
    • 12.3.2. Ophthalmology Clinics

13. Biosurgery Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biosurgery Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biosurgery Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biosurgery Market

17. China Biosurgery Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Advanced Medical Solutions Group plc
  • 18.6. Artivion, Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Baxter International Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. BioCer Entwicklungs-GmbH
  • 18.11. Boston Scientific Corporation
  • 18.12. Cardinal Health, Inc.
  • 18.13. Corza Medical GmbH
  • 18.14. CryoLife, Inc.
  • 18.15. CSL Limited
  • 18.16. Hemostasis, LLC
  • 18.17. Integra LifeSciences Holdings Corporation
  • 18.18. Johnson & Johnson
  • 18.19. Kuros Bioscience AG
  • 18.20. Medtronic plc
  • 18.21. Pfizer Inc.
  • 18.22. RTI Surgical, Inc.
  • 18.23. Samyang Holdings Corporation
  • 18.24. Sanofi SA
  • 18.25. Smith & Nephew plc
  • 18.26. Stryker Corporation
  • 18.27. Teleflex Incorporated
  • 18.28. Tissue Regenix Ltd
  • 18.29. Vivostat A/S

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOSURGERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOSURGERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOSURGERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOSURGERY MARKET SIZE, BY HEMOSTATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOSURGERY MARKET SIZE, BY SEALANTS & ADHESIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOSURGERY MARKET SIZE, BY TISSUE GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOSURGERY MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOSURGERY MARKET SIZE, BY FIBRIN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOSURGERY MARKET SIZE, BY GELATIN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOSURGERY MARKET SIZE, BY SYNTHETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOSURGERY MARKET SIZE, BY NONRESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOSURGERY MARKET SIZE, BY FULLY RESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOSURGERY MARKET SIZE, BY PARTIALLY RESORBABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOSURGERY MARKET SIZE, BY BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOSURGERY MARKET SIZE, BY VALVE REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOSURGERY MARKET SIZE, BY HERNIA REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOSURGERY MARKET SIZE, BY WOUND REPAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOSURGERY MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOSURGERY MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOSURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOSURGERY MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOSURGERY MARKET SIZE, BY SPINAL FUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIOSURGERY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOSURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOSURGERY MARKET SIZE, BY DENTAL CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOSURGERY MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIOSURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BIOSURGERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOSURGERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 218. GCC BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 219. GCC BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 220. GCC BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. G7 BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 250. G7 BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 251. G7 BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. G7 BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. NATO BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. NATO BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. NATO BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL BIOSURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA BIOSURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA BIOSURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA BIOSURGERY MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA BIOSURGERY MARKET SIZE, BY RESORBABILITY, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA BIOSURGERY MARKET SIZE, BY RESORBABLE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA BIOSURGERY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA BIOSURGERY MARKET SIZE, BY CARDIOVASCULAR SURGERY, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA BIOSURGERY MARKET SIZE, BY GENERAL SURGERY, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA BIOSURGERY MARKET SIZE, BY MINIMALLY INVASIVE SURGERY, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA BIOSURGERY MARKET SIZE, BY ORTHOPEDIC SURGERY, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BIOSURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BIOSURGERY MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)